Investigation of Efficacy of Secukinumab in Patients With Moderate to

Status Completed

Clinical Trial Summary

The overall aim of this study is to assess the effects of a new treatment called Secukinumab in adults suffering from moderate to severe atopic dermatitis. Furthermore, the study shall support the extension of the approval for Secukinumab from psoriasis to atopic dermatitis. The effectiveness of Secukinumab is determined on the reduction of the eczema score EASI 50 (Eczema Area and Severity Index, a tool to measure the severity of atopic dermatitis) at week 4.

Clinical Trial Description

Secukinumab is a humanized anti-IL-17A monoclonal antibody. Since Secukinumab is well established in the therapy of psoriasis with a highly favorable benefit to risk ration and IL-17 has been described in atopic dermatitis this study aims to investigate the effects of anti-IL-17 in atopic dermatitis. This is a randomized, placebo-controlled, multicenter, double-blinded study to evaluate the efficacy and safety of subcutaneous Secukinumab compared to placebo in 45 adults with atopic dermatitis. The study consists of 3 periods: a screening period of at least -14 days and up to -35 days, and a treatment period of 16 weeks and a follow-up period of additional 8 weeks. During the screening period eligibility of the patients is confirmed. Eligible patients are randomized 2:1 to treatment arm A or B at Day -7 (+2 to -15) during the randomization visit. Secukinumab (Cosentyx®) will be used according to the official label and SmPC (Summary of Product Characteristics). Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints visits are performed at weeks 20 and 24. Placebo will be administered as 2 subcutaneous injections. Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints visits are performed at weeks 20 and 24. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03568136
Study type	Interventional
Source	GWT-TUD GmbH
Contact
Status	Completed
Phase	Phase 2
Start date	September 18, 2018
Completion date	May 4, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03563066` - Effect of Benralizumab in Atopic Dermatitis	Phase 2
Terminated	`NCT04086121` - A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032	Phase 2
Recruiting	`NCT04011215` - Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)	N/A
Completed	`NCT04635072` - Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis	Early Phase 1
Completed	`NCT02916888` - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists	N/A
Completed	`NCT01945086` - A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis	Phase 2
Completed	`NCT00541255` - A Long-Term Examination of Asthma From Childhood Through Adolescence
Terminated	`NCT04990440` - A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis	Phase 2
Completed	`NCT02900131` - Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients	Phase 2
Recruiting	`NCT01631617` - Effects of Treatments on Atopic Dermatitis	Phase 2
Completed	`NCT03672383` - Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)	N/A
Completed	`NCT03634345` - Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.	Phase 1
Enrolling by invitation	`NCT04761978` - Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis
Completed	`NCT03663673` - Effect of Different Skin Creams on TEWL	Phase 1
Recruiting	`NCT05177744` - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed	`NCT03720470` - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	Phase 3
Completed	`NCT02637206` - Skin Irritation Study of GSK2894512 Cream	Phase 1
Completed	`NCT05544591` - Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis	Phase 2
Completed	`NCT05094700` - A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants	N/A
Completed	`NCT02590289` - A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis — Secu_in_AD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms